⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

May 28, 2026HaematologicaOpen Access

Response to Comment on: “Is it time to reduce the doxorubicin dosage in Hodgkin lymphoma therapy?”

View Full Paper

Ask AI

Bookmark

Share

Key Points

The commentary addresses the need to evaluate doxorubicin dosage in Hodgkin lymphoma treatment and its potential impact on patient outcomes.
Evaluating current literature on doxorubicin administration in Hodgkin lymphoma.
Discussing opposing viewpoints on dosage reduction and associated risks.
Analyzing toxicity and efficacy data from previous studies.
Reduction in doxorubicin dosage may lead to decreased toxicity for patients.
Considered potential benefits must be balanced against treatment effectiveness.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Comment discusses reducing doxorubicin dosage in Hodgkin lymphoma therapy, suggesting potential benefits.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Eldad J. Dann (2026) studied this question.

synapsesocial.com/papers/6a1a7fce0307b78509431ec4 https://doi.org/10.3324/haematol.2026.301249

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Is it time to increase the liposomal doxorubicin dosage for frontline therapy in young adults and adults with classic Hodgkin lymphoma? Comment on: “Is it time to reduce the doxorubicin dosage in Hodgkin lymphoma therapy?”Original Research · 2026
2Response to Comment on: “Treatment of therapy-related acute myeloid leukemia and acute myeloid leukemia with myelodysplasiarelated changes: a comparative analysis of higher-dose intensive 7+3 induction chemotherapy versus liposomal cytarabine and daunorubicin”Original Research · 2026
3Response to Comment on: “Decreasing excess mortality after allogeneic stem cell transplantation for acute leukemia”Original Research · 2026
4Preserving anthracycline-containing treatment in older patients with classical Hodgkin lymphoma: a role for liposomal doxorubicin. Comment on: "Age, anthracycline and mortality in 28,000 classic Hodgkin lymphoma patients: cohort study of a complete population"Cohort Study · 2026
5Developing Drugs to Decrease the Toxicity of Chemotherapyeditorial · 2001 · 101 citations

Response to Comment on: “The evolution of the complete blood count: have we gone too far?”2026
Anthracycline-Induced Cardiotoxicity1997
Who needs bleomycin in classic Hodgkin lymphoma? Comment on: “Bleomycin omission in limited-stage classic Hodgkin lymphoma with negative PET scan after two cycles of ABVD”2026
The importance of preparation for or achieving accreditation for small and high volume hematopoietic cell transplantation programsHaematologica · 2026
BCL6 in B-cell lymphomas: old target, new tricks?Haematologica · 2026

More from Haematologica

More from Rambam Health Care Campus